50岁与65岁开始接种23价肺炎球菌多糖疫苗及流感疫苗的成本效果:一项比较模型研究
研究采用马尔可夫模型模拟10万名50至85岁老年人,比较5种疫苗接种策略(含50岁或65岁开始接种PPV23联用或不联用年度流感疫苗)的成本效果。结果所有策略相比不接种均具成本效果,ICER均低于阈值(每获得1个QALY 24,302美元);其中50岁和65岁接种PPV23并每年接种流感疫苗的策略,即使与现行接种程序相比仍具成本效果。
要点
- 所有疫苗接种策略相比不接种均具成本效果,ICER均低于每QALY 24,302美元的阈值。
- 策略1(50岁和65岁接种PPV23并每年接种流感疫苗)相比现行程序(策略2)每获得1个QALY需多花费195.3美元。
- 策略3和策略4相比策略2效果更差且成本增加。
核心结论
- 所有疫苗接种策略均具成本效果,其中50岁和65岁接种PPV23并每年接种流感疫苗的策略,即使与现行接种程序相比仍具成本效果。
- 这些发现有助于为疫苗接种策略的设计和实施提供信息。
研究设计与样本
- 采用马尔可夫模型模拟10万名50至85岁的假设老年人群。
- 比较5种策略:①50岁和65岁每年接种流感疫苗并接种PPV23;②65岁每年接种流感疫苗并接种PPV23(与现行接种程序相似);③50岁和65岁接种PPV23;④65岁接种PPV23;⑤不接种。
主要发现
- 与不接种相比,策略1至策略4每获得1个QALY分别节省49.5美元、94.9美元、584.3美元和1114.2美元。
- 与策略2相比,策略1每获得1个QALY需多花费195.3美元。
- 与策略2相比,策略3和策略4效果更差且成本增加。
- 与不接种相比,所有策略的ICER均低于每QALY 24,302美元的阈值。
关键数值与推荐
- 成本效果阈值为每获得1个QALY 24,302美元,提取自既往文献。
- 采用蒙特卡洛模拟进行概率敏感性分析。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Pneumococcal infection is a leading cause of morbidity and mortality. We aimed to evaluate the cost-effectiveness of 23-valent polysaccharide vaccine (PPV23) together with influenza vaccination or pneumococcal vaccination alone in adults starting from 50 years vs. 65 years in Hong Kong. METHODS: A hypothetical population of 100,000 older adults was included in a Markov model with age ranging from 50 to 85 years to calculate the cost and quality-adjusted life-years (QALYs) gained for vaccination strategies, including: (1) annual influenza vaccine and PPV23 at 50 and 65 years; (2) annual influenza vaccine and PPV23 at 65 years (similar with the current vaccination programme); (3) PPV23 at 50 and 65 years; (4) PPV23 at 65 years; and (5) no vaccination. We evaluated the incremental cost-effectiveness ratio (ICER) and used Monte Carlo simulation for probabilistic sensitivity analysis. The cost-effectiveness threshold was extracted from previous literature. RESULTS: In comparison with no vaccination, all strategies were cost-effective with ICERs less than the threshold (US$24,302 per QALY gained). When compared with no vaccination, strategies 1-4 saved US$ 49.5, US$ 94.9, US$ 584.3, and US$ 1114.2 to gain one QALY respectively. In comparison with strategy 2, strategy 1 spent US$ 195.3 to gain one QALY, whilst strategies 3 and 4 showed less effectiveness with increased costs. CONCLUSIONS: All vaccination strategies were cost-effective, among which the strategy of PPV23 at 50/65 years with annual influenza vaccine was cost-effective even in comparison with current vaccination programme. These findings could help inform the design and implementation of vaccination strategies.
引用
- Ding H, Huang J, Ngai CH, et al. The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study. Vaccine. 2022. PMID: 35094867. doi:10.1016/j.vaccine.2022.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。